GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Research & Development

NovMetaPharma Co (XKRX:229500) Research & Development : ₩3,153.61 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NovMetaPharma Co's Research & Development for the six months ended in Dec. 2023 was ₩3,153.61 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₩3,153.61 Mil.


NovMetaPharma Co Research & Development Historical Data

The historical data trend for NovMetaPharma Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Research & Development Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only 8,954.96 2,319.97 2,095.44 2,567.18 3,153.61

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only 8,954.96 2,319.97 2,095.44 2,567.18 3,153.61

NovMetaPharma Co Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₩3,153.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovMetaPharma Co  (XKRX:229500) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


NovMetaPharma Co Research & Development Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co (XKRX:229500) Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co (XKRX:229500) Headlines

No Headlines